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Abstract
Background: Implementing Chlamydia trachomatis screening in the Netherlands has been a point of debate for
several years. The National Health Council advised against implementing nationwide screening until additional data
collected from a pilot project in 2003 suggested that screening by risk profiles could be effective. A continuous
increase in infections recorded in the national surveillance database affirmed the need for a more active approach.
Here, we describe the rationale, design, and implementation of a Chlamydia screening demonstration programme.
Methods: A systematic, selective, internet-based Chlamydia screening programme started in April 2008. Letters are
sent annually to all 16 to 29-year-old residents of Amsterdam, Rotterdam, and selected municipalities of South
Limburg. The letters invite sexually active persons to login to http://www.chlamydiatest.nl with a personal code
and to request a test kit. In the lower prevalence area of South Limburg, test kits can only be requested if the
internet-based risk assessment exceeds a predefined value.
Results: We sent invitations to 261,025 people in the first round. One-fifth of the invitees requested a test kit, of
whom 80% sent in a sample for testing. The overall positivity rate was 4.2%.
Conclusions: This programme advances Chlamydia control activities in the Netherlands. Insight into the feasibility,
effectiveness, cost-effectiveness, and impact of this large-scale screening programme will determine whether the
programme will be implemented nationally.
Background
Screening for Chlamydia trachomatis aims at early
detection and treatment of asymptomatic infections,
which limit the spread of infection in the population
and reduce complications in infected individuals [1,2].
A large population-based study in four regions of the
Netherlands in 2003 (the C. trachomatis pilot study)
showed an overall prevalence of 2.1% of C. trachomatis
among participants aged 15-29 years, with positivity
rates in urban areas five times as high as those in rural
areas (3.2% vs. 0.6%) [3]. In this study, positivity corre-
lated closely with several risk factors such as increasing
numbers of sex partners, female gender, and specific
ethnic background (up to 8% among Surinamese and
Dutch Antillean participants). Outcomes of this study
were used to develop a risk score that allowed a more
selective - and therefore more cost-effective - screening
model [4].
In 2006, the National Health Council, considering the
substantial increase in C. trachomatis infections, recon-
sidered its reluctant position against screening, and
favoured developing a demonstration project to increase
the level of C. trachomatis testing in the Netherlands and
to supplement the then current C. trachomatis testing,
which was mainly provided by general practitioners
(GPs) and sexually transmitted infection (STI) clinics [5].* Correspondence: jvanbergen@soaaids.nl
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In this paper, we describe the rationale, design, and
roll-out of a large-scale register-based, systematic, selec-
tive screening programme, in which the internet plays a
major role. The participation criteria differ in rural and
urban areas. We also give a brief outline of process and
impact evaluation studies that accompany the screening,
and we present the results of the first screening round.
Methods
Design of the screening programme
STI AIDS Netherlands coordinates the screening pro-
gramme, and the local Public Health Services carry it
out, expanding the screening in a phased implementa-
tion (stepped wedge, cluster, randomised design). The
Centre for Infectious Disease Control, a section of the
National Institute for Public Health and the Environ-
ment (RIVM), is responsible for the formal evaluation
process. An advisory committee consisting of experts
and other relevant parties, including the Ministry of
Health, support the executive board of the screening
programme. The Ethics Committee of the Free Univer-
sity of Amsterdam (METC number: 2007/239) has
approved the study, which conforms to national and
international legislation. Participants provide online
informed consent. The time frame of the demonstration
project is 2008-2010.
Rationale for register-based screening
We chose to organise the screening as register-based
(i.e. all individuals registered in the target population are
actively approached for participation) as opposed to
opportunistic (screening offered during consultations or
outreach).
The only two published randomised controlled trials
(RCTs) investigating the individual benefits of screen-
ing assessed systematic screening [6,7] and have shown
a reduction in pelvic inflammatory disease (PID).
A new trial has recently been added to this body of
evidence [8]. The programme coverage (or effective
test rate) is critical for achieving not only individual
benefit (reduction of complications by means of early
diagnosis and treatment), but also a reduction of trans-
mission at the population level. The reported popula-
tion coverage of ongoing opportunistic programmes is
limited [9]. In contrast, a Danish study has shown that
the eligible population was 11 times as likely to be
tested in home-based screening as in the opportunistic
testing that doctors offer during routine care [10]. In
addition, a recent review shows that the evidence base
for opportunistic screening is poor [11,12]. We have
demonstrated the feasibility and acceptability of regis-
ter-based systematic screening in the Netherlands
via the Municipal Health Services in a previous
study [3,13].
Rationale for population selection for screening
The demonstration programme has been implemented in
three regions: two large cities (Amsterdam and
Rotterdam) and one somewhat more rural area (South
Limburg). Each year, all residents aged 16-29 years
receive an invitation letter. Our previous research showed
that prevalence in the population of highly urbanised
areas in the Netherlands is well above 3% [3]. People
living in Amsterdam and Rotterdam are advised to parti-
cipate if they are (or have been) sexually active. In areas
of lower population density, the population prevalence
is between 0.6% and 2%, so that selective screening
based on risk profiles is required to reach a better
cost-effectiveness profile [3,4]. Therefore, eligibility for
screening in South Limburg is assessed on the basis of
individual risk scores calculated from invitees’ informa-
tion online. The web-based questionnaire asks nine ques-
tions about demographics and sexual behaviour, and
each item contributes to the risk score (Additional file 1).
The invitee can request a test kit only if the risk score
reaches a predefined value. The prediction rule for this
selective screening is based on previous research [4] and
aims at a C. trachomatis positivity yield of 4-5%.
We chose to include both men and women in the
screening. Population studies show prevalence rates
among men comparable to those among women.
Including men in the screening makes them part of the
solution rather than the problem [14]. Models show that
screening both men and women can have more impact
than screening only women [15]. However, the impact
of screening both men and women on community pre-
valence has yet to be demonstrated in real life. In fact, a
recent literature review called for more high-quality
RCTs to ascertain the impact on individual complica-
tions like PID and infertility, as well as the impact on
community prevalence [12]. We are expanding our
screening area by area, and we are including all eligible
residents of a geographically confined area within a lim-
ited time. This strategy covers social and sexual net-
works in order to grasp any community impact of
accelerated screening.
Logistics
Figure 1 presents the framework of the logistics. The
local Public Health Services send invitations to all 16
to 29-year-olds in Amsterdam, Rotterdam, and South
Limburg. Municipal population registers supply the
addresses. The order of invitations is cluster-rando-
mised per area or municipality according to postal
codes lists within clusters in each of the three partici-
pating regions. The invitations contain an information
leaflet and a letter, advising those who are (or have
been) sexually active to participate. The invitation let-
ters provide a unique ID number (login code) that
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enables the invitee to request a test kit at http://www.
chlamydiatest.nl (Figure 2). The invitation letter and
information materials (text and website) have been
developed and pretested with the relevant age, sex, and
cultural groups. In the lower prevalence area, South
Limburg, anyone who visits the website must first do a
short online risk assessment, and can only request a
test kit if the risk score reaches a predefined level of 6
or more, compatible with an estimated positivity rate
of 4-5% (see Additional file 1).
Those who have not reacted to the initial invitation
within 4 weeks receive a reminder invitation. A remin-
der is e-mailed to those who do not send a sample to
the laboratory within 2 weeks of their request for a test
kit; a second reminder is e-mailed 1 week later. Invitees
who send a sample to the laboratory receive an e-mail
and/or SMS to inform them when their test result is
available online. Chlamydia trachomatis positive partici-
pants can print the PDF letter with their test results and
information for health care providers. The test results
Figure 1 Operational flowchart of the Chlamydia screening programme.
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on the website can only be accessed by personal login. If
the test results are not accessed within 14 days, a remin-
der e-mail is sent. Everyone with a positive result who
has not checked the test result within 4 weeks is sent a
letter with the result at the address provided.
The test kit includes a home sample kit (Figure 3; men:
urine sample, women: vaginal swab or urine sample). The
participants send the self-collected samples to the regio-
nal laboratory in an envelope suitable for mailing biologi-
cal materials. The three participating laboratories are all
certified, take part in quality control programmes and use
certified nucleic acid amplification techniques according
to the manufacturer’s guidelines. The one laboratory that
uses pooling retests positive pools individually. The two
laboratories that do not pool confirm positive tests with a
second test on the same specimen.
The patient’s GP provide treatment, but if a partici-
pant prefers, the local STI centre provides it. The cur-
rent sex partners of participants with positive test
results are advised to be treated simultaneously or seek
prompt testing and treatment. Previous partners are
notified predominantly by patient referral. Additionally,
participants with positive test results can also use the
website, anonymously if they wish, to notify previous
sex partners of the last 6 months via e-mail. These part-
ners are offered testing within the existing screening
programme. Participants who test positive receive a new
test kit automatically after 6 months.
Data collection and evaluation
The programme’s central database automatically stores
data from all invitees. The database includes data per-
taining to progression through the screening process
and data from the local population registers, the labora-
tories, and the company responsible for handling the
mailings. The central database enables process monitor-
ing, evaluation, and uploading of regular time-framed
overviews of key outcomes and indicators of programme
performance. Data obtained from online questionnaires
for participants and mailed questionnaires for non-
responders, including characteristics such as self-
reported sexual history and clinical symptoms, are also
Figure 2 Website of the Chlamydia screening programme.
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linked to the central database to allow for more detailed
analyses.
The evaluation of the screening implementation con-
sists of various components. A detailed description of
the design of the evaluation is given elsewhere [16]. The
first part concerns process evaluation, including non-
response and acceptability studies [17]. In the second
part, the effects of screening are evaluated. For evalua-
tion purposes, we chose a phased implementation of the
screening. This ‘stepped-wedge design’ enables a
sequential roll-out in geographical clusters (neighbour-
hoods), randomised within a number of periods. The
design allows for:
1. Estimation of the effect of one or two screening
rounds on the population prevalence of C. trachomatis
and self-reported PID.
2. Determination of trends of participation in different
screening rounds.
Figure 3 Polymed plastic envelope and test materials.
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3. Assessment of baseline ecological trends among
those who have not received a screening invitation at
the end of the second screening round.
Other important components of the evaluation are the
modelling of positivity and prevalence, and the cost-
effectiveness analyses.
Results
The first screening round
Between April 2008 and February 2009, 261,025 people
were sent an initial invitation for the first screening
round (140,058 in Amsterdam, 107,806 in Rotterdam,
and 13,161 in South Limburg). Overall, 21% of those
invited were 16-20 years old, 37% were 20-24 years old,
and 42% were 25-29 years old; 52% of the invitees were
female. One percent of the invitational letters were
returned as undeliverable.
Request rate
The request rate - i.e. the proportion of the invited
population requesting a test kit - was 11.9% within
4 weeks after the initial invitation. The remaining invi-
tees who did not react within 4 weeks received a remin-
der invitation, after which an additional 8.3% requested
a test kit. In total, 52,741 people requested test kits
upon invitation. The overall request rates were 20.5% in
both urban areas compared with 13.8% in sub-urban
South Limburg. In this region, eligibility for a test kit
was dependent on a sufficiently high risk score. Of the
22.5% of the invitees who filled in the online risk score,
63% were eligible. In all three regions, the request rates
were substantially higher among women than among
men (25.8% vs. 14.1%, c2 p < 0.0001). They were also
higher among those aged over 20 years than among
younger groups (22% vs. 13.4%, c2 p < 0.0001; Table 1).
The median time lapse between the invitation and
request for a test kit was 18 days (range 0-428 days). On
average, people requested a test kit 28 days after the
invitation [standard deviation (SD) ± 30 days]. Remin-
ders significantly increased the requests for a test kit:
33% of the requests for test kits were received after the
reminder was sent (Figure 4).
Effective participation rate
Of those who requested a test kit, 41,637 (79%) sent in a
sample. This test uptake of 79% translates into a pro-
gramme coverage (effective participation or test rate) of
16% of the invited population being tested in the first
screening round.
The participation rate was considerably higher among
women (21.0%) than among men (10.4%, p < 0.0001),
and among those 20 years old and older (17.6%) than
among those less than 20 years old (9.9%, p < 0.0001).
The trends were similar across regions, but there were
significant differences in overall participation rates
between regions (Table 2).
The median time lapse between requesting a test kit
and returning a sample to the laboratory was 11 days
(range 0-390; mean 17 days, SD ± 19). Reminders sig-
nificantly contributed to the sending of samples: 39%
of samples were received after the reminder invitation
was sent. See Op de Coul et al. [17] for more detailed
and time-framed monitoring indicators of process
performance.
Positivity for Chlamydia trachomatis
The laboratories processed 96% of the samples within
the predefined target of 10 working days, and test
results were made available online. A total of 1758 peo-
ple tested positive for C. trachomatis, which resulted in
an overall positivity rate of 4.2% (95% CI 4.0-4.4%).
In this first screening round, the positivity rate was
significantly lower among men [3.8% (95% CI 3.5-
4.15%)] than among women [4.4% (95% CI 4.2-4.7%),
p = 0.003]. Those younger than 20 years were signifi-
cantly more likely to have positive test results (7.3%)
than those 20 years old or older (3.8%, p < 0.0001). In
particular, younger girls were more likely to test positive
(8%). We also found substantial differences in the posi-
tivity rates across the participating regions (Table 3).
Table 1 Proportions of the invited population requesting test kits in the Chlamydia screening implementation, 2008-
2009
Amsterdam Rotterdam South Limburg* All regions
Men Women Total Men Women Total Men Women Total Men Women Total
n 65268 74790 140058 52692 55114 107806 6848 6313 13161 124808 136217 261025
Age group (years) Proportions by region, gender, and age groups (in percentages)
16-19 9.1 18.4 13.9 8.9 17.6 13.2 5.2 17.7 11.3 8.8 18.0 13.4
20-24 14.8 27.9 22.0 14.2 26.1 20.3 9.2 21.7 15.1 14.2 26.9 21.0
25-29 17.7 30.4 24.5 16.3 26.9 21.7 10.0 19.1 14.4 16.8 28.6 23.0
All age groups 15.0 27.2 21.5 13.8 24.5 19.3 8.4 19.6 13.8 14.1 25.8 20.2
*In this region, 22.5% of the total invited population completed the online risk score, and 63% of the scores were high enough for a test kit request.
van Bergen et al. BMC Infectious Diseases 2010, 10:293
http://www.biomedcentral.com/1471-2334/10/293
Page 6 of 10
Treatment
Ninety-five percent of the participants checked their test
results online, and 90% did so within 7 days after being
notified by e-mail that the results were available online.
Preliminary analyses of the questionnaires, filled in by
43% of all those who were C. trachomatis positive, indi-
cated that an estimated 91% of them saw a physician
(82% went to their GP). Of those who consulted a physi-
cian, 98% received treatment. Patient referral is the
mode of tracing contacts in the Netherlands, but anon-
ymous, web-based, partner notification via the pro-
gramme was also possible. The patients with C.
trachomatis provided e-mail addresses for notification of
382 non-regular sex partners of the previous 6 months.
Altogether, 125 of the notified partners (33%) requested
a test kit, of whom 107 (86%) sent in a sample for C.
trachomatis testing. Twenty-nine of these samples (27%)
tested positive.
Participants who were C. trachomatis positive were
automatically sent a new test kit at the address provided
6 months after the initial test. Of these participants,
1152 (68%) sent in a lab sample, and 95 C. trachomatis
test results were positive - a positivity rate of 8.2% (95%
CI 6.6-9.7%).
Acceptability and usability studies are currently in
progress among both participants and non-responders.
Preliminary data indicate overall good acceptability, with
participants showing positive attitudes towards the
screening programme and communication via the web-
site and by SMS. In our postal non-response study, we
did not find indications that participation in the screen-
ing was hampered by limited access to the internet.
Further detailed analyses regarding acceptability, pro-
cess, and non-response will generate more in-depth
insight into factors associated with participation, and
coverage. These analyses will be reported separately.
Discussion
After taking the best available evidence into account and
after the pilot study provided insight into the population
prevalence of C. trachomatis in urban and rural areas,
we embarked on a register-based, systematic, selective,
internet-based programme for the Chlamydia screening
implementation (CSI). The entire population aged 16-29
Table 2 Proportions of the invited population who provided samples in the Chlamydia screening implementation,
2008-2009
Amsterdam Rotterdam South Limburg* All regions
Men Women Total Men Women Total Men Women Total Men Women Total
n 65268 74790 140058 52692 55114 107806 6848 6313 13161 124808 136217 261025
Age group (years) Proportions by region, gender, and age groups (in percentages)
16-19 5.9 14.1 10.1 6.3 13.5 9.9 3.9 14.4 9.0 6.0 13.8 9.9
20-24 10.4 23.1 17.4 10.9 20.9 16.1 6.5 18.1 12.0 10.4 22.0 16.6
25-29 13.3 25.4 19.8 12.6 21.8 17.3 7.8 15.9 11.7 12.8 23.6 18.5
All age groups 10.8 22.4 17.0 10.5 19.6 15.2 6.2 16.2 11.0 10.4 21.0 16.0







































Figure 4 Time between invitation and request of a testing kit.
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years in geographically defined areas is annually invited
for screening to include any community effect of
repeated screening rounds on prevalence. Only sexual
active people are advised to participate, and people
residing in lower prevalence areas must take part in an
online risk assessment in order to request a test kit. The
screening is being rolled out in randomised clusters in a
stepped-wedge design to enable impact evaluation.
In the first screening round, the 52,741 people who
requested a test kit represented 20% of the invitees.
Almost 80% of those with a request sent in a sample, so
that the overall participation rate was 16%. Participation
among women (21%) was double that among men
(10%). This overall participation rate is lower than the
rate in the pilot study (30%) [3]. Differences in participa-
tion may be partially explained by differences in offering
the testing kit. In the pilot study, test kits were sent
directly with the invitation instead of having the test kits
requested via internet. An advantage of our current
approach was lower cost: most test kits are not used if
sent to every eligible person. A study in Denmark has
also found that direct mailing compared to requesting a
kit for home-based testing lowered the participation rate
a little for women, but substantially for men [10].
Another factor that contributed to the lower participa-
tion rate is the selective nature of our screening: only
sexually active people are eligible, and in the lower preva-
lence area of South Limburg, only sexually active people
with a risk score of a predefined value may participate.
For example, in the group of 16-year-olds, only an esti-
mated 40% can consider participation because the rest
are not yet sexually active [18]. Nonetheless, the overall
effective test rate of 16% seems low and makes it even
more important to know who is participating and who is
not. Our acceptability and non-response studies will
attempt to determine whether participation is biased
toward the ‘worried well’ and whether non-responders
make valid ‘informed’ decisions not to participate if they
perceive themselves at lower risk. Moreover, our future
studies will have to show if this systematic screening,
which is additional to the existing testing in health facil-
ities, can reduce community prevalence.
We are cautious about international comparisons of
screening coverage because programme designs may dif-
fer and denominators may not be comparable. We use
the total population of the relevant age group as the
denominator. Sometimes denominators for coverage
include only sexually active people or - as in opportunis-
tic programmes - the people who accepted the offer of a
test or the attendees at health facilities.
Chlamydia trachomatis positivity among the partici-
pants in the screening programme is 4.2%. We encoun-
tered substantial differences within and between the two
large cities, and we are currently analysing community
risk profiles. In the lower-prevalence area of South Lim-
burg, selection by risk score on the internet worked well
and increased positivity from 1.3% in the pilot study
population to 5.1% in the current screening programme.
The positivity rate for the 25 to 29-year-olds is 2.9%,
which is substantially lower than that among younger
people. Cost-effectivity analyses will have to show
whether this age group should be included for universal
screening in very urbanised areas, or whether this group
needs the more selective screening that we do in less
urbanised areas.
Compared to the 16% overall participation rate, a
reassuring finding was that 68% of those who were
C. trachomatis positive did participate when they auto-
matically received a re-screening invitation 6 months
later. As others have reported [19,20], the re-infection
rate was high (8.2%). Reported treatment rates are
well above 90%, and they are in line with the well-
documented treatment rates in our pilot study [21].
These facts pinpoint the need for early regular testing
of this group, as well as for more effective patient
management, including counselling and partner man-
agement [22,23].
The use of internet, SMS, and e-mail services made
communication flexible and ‘future proof’ for the next
young generations. These services provided new oppor-
tunities for reminders and partner notification. The
development of computer software and the project’s
database enable easy adaptation of the screening in time
and expansion to other geographic areas in the future.
Table 3 Proportions of positive samples for the various groups in the Chlamydia screening implementation, 2008-2009
Amsterdam Rotterdam South Limburg* All regions
Men Women Total Men Women Total Men Women Total Men Women Total
n 7050 16777 23827 5544 10817 16361 426 1024 1450 13020 28618 41638
Age group (in years) Positive samples per group (in percentages)
16-19 5.2 6.9 6.4 6.3 9.9 8.7 5.2 4.5 4.7 5.7 8.0 7.3
20-24 3.9 4.3 4.2 4.4 5.9 5.4 5.6 5.9 5.8 4.1 5.0 4.7
25-29 2.6 2.5 2.5 3.7 3.6 3.6 5.4 4.3 4.7 3.1 2.9 3.0
All age groups 3.3 3.7 3.6 4.3 5.5 5.1 5.4 5.0 5.1 3.8 4.4 4.2
*In this region, 22.5% of the total invited population completed the online risk score, and 63% of the scores were high enough for a test kit request.
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Conclusions
We have reported the rationale, design, and results of the
first screening round of our selective, systematic, internet-
based programme for C. trachomatis screening. We
designed the programme to show the impact on issues
such as population prevalence and self-reported PID,
thereby contributing to the body of evidence for or against
screening. More evidence of the impact and cost-effectivity
of real-life comprehensive programmes for C. trachomatis
screening is urgently needed. Currently, much of the evi-
dence in favour of screening derives from selected studies,
the strengths of which have been questioned [12]. Most
studies involve a follow-up of only one screening round
and focus on prevention of PID as an end-point, which is
only one of the goals of screening. Our programme is now
entering the next phase: we are implementing the second
screening round. This will help us gain more evidence
about the sustainability of a screening programme and the
rates of participation and positivity in successive screening
rounds. The outcome of this 3-year demonstration pro-
gramme will be crucial for the decision about a national
roll-out of C. trachomatis screening in the Netherlands.
Additional material
Additional file 1: Calculation of risk score in the low prevalence
area.
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